Daratumumab SC

DRUG8 trials

Sponsors

Janssen Research & Development, LLC, Incyte Corporation, Weill Medical College of Cornell University, National Cancer Institute (NCI), Carl Ola Landgren, MD, PhD

Conditions

AL AmyloidosisAmyloidLymphoma, Primary EffusionMultiple MyelomaRefractory AL AmyloidosisRefractory Multiple MyelomaRelapse Multiple MyelomaRelapsed or Refractory Multiple Myeloma

Phase 1

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

TerminatedNCT03837509

Incyte CorporationRelapsed or Refractory Multiple Myeloma

Start: 2019-09-25End: 2022-04-05Updated: 2025-11-04

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Active, not recruitingNCT05050097

Janssen Research & Development, LLCMultiple Myeloma

Start: 2021-09-22End: 2027-04-07Updated: 2026-08-28

Phase 2

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Active, not recruitingNCT04270175

Weill Medical College of Cornell UniversityAL Amyloidosis, Amyloid, Refractory AL Amyloidosis

Start: 2021-04-14End: 2028-01-01Updated: 2026-02-27

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Active, not recruitingNCT04302324

Weill Medical College of Cornell UniversityMultiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma

Start: 2021-10-28End: 2027-12-28Updated: 2026-05-20

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

RecruitingNCT05907759

National Cancer Institute (NCI)Lymphoma, Primary Effusion

Start: 2024-07-10End: 2035-12-01Target: 28Updated: 2026-08-25

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

RecruitingNCT06100237

Carl Ola Landgren, MD, PhDMultiple Myeloma

Start: 2023-12-04End: 2029-12-31Target: 50Updated: 2026-02-23

Phase 3

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

CompletedNCT02195479

Janssen Research & Development, LLCMultiple Myeloma

Start: 2014-12-09End: 2024-08-07Updated: 2025-08-22

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

CompletedNCT02252172

Janssen Research & Development, LLCMultiple Myeloma

Start: 2015-02-16End: 2024-10-02Updated: 2025-10-20

Related Papers

Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).

Journal of Clinical Oncology2026-05-28

Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE

Blood Advances2026-05-05

Daratumumab for relapsed/refractory primary effusion lymphoma, plasmablastic lymphoma and multicentric castleman disease.

Blood2025-11-03

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Blood2025-11-03

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Blood2025-11-03

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

2025-04-094 citations

AL Amyloidosis: Current Treatment and Outcomes.

2025-03-032 citations

Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: <scp>MAIA</scp> Final Analysis of Patient‐Reported Outcomes

European Journal Of Haematology2025-02-143 citations

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.

2025-01-155 citations

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Blood2024-11-057 citations

Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Blood2024-11-052 citations

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Blood2024-11-051 citations

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood2024-11-05

Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.

2024-09-02

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Blood2023-11-0239 citations

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Blood2023-11-02

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)

HemaSphere2023-05-012 citations

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL

HemaSphere2023-05-012 citations

Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma

Future Oncology2023-04-012 citations

Multiples Myelom: Korrelation zwischen minimaler Resterkrankung und progressionsfreiem Überleben

Kompass Onkologie2023-01-01

31 more papers not shown